Description
Lomefloxacin is a kind of fluoroquinolone antibiotics used for the
treatment of bacterial infections such as bronchitis and urinary
tract infection. It can also used to prevent the urinary tract
infections prior surgery. It has bactericidal effect against a wide
range of gram-negative and gram-positive organisms. It takes effect
through interfering with the normal function of the bacteria enzyme
DNA gyrase and topoisomerase IV, further inhibiting the
transcription and replication of bacterial DNA. This effect results
in strand breakage of bacterial chromosome, supercoiling and
resealing, further causing bacteria death.
References
https://en.wikipedia.org/wiki/Lomefloxacin
https://www.drugbank.ca/drugs/DB00978
Description
Lomefloxacin is a once-daily, third-generation quinolone antibiotic useful in the treatment
of bacterial infections. The new fluorinated quinolone does not interfere with the
metabolism of theophylline; it is efficacious against pathogens resistant to cephalosporins,
penicillins and aminoglycosides.
Chemical Properties
colorless Needles
Originator
Hokuriku Seiyaku (Japan)
Definition
ChEBI: A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.
Manufacturing Process
A mixture of 1.00 g of 1-ethyl-6,7,8-trifluoro-1,4-dihydro-4-oxoquinoline-3-
carboxylic acid, 1.10 g of 2-methylpiperazine and 10 ml of pyridine was
heated for 15 minutes under reflux. The reaction mixture was evaporated and
methanol was added to the residue. The precipitate was filtered and
recrystallized from ethanol to give 0.36 g of the 1-ethyl-6,8-difluoro-1,4-
dihydro-7-(3-methyl-1-piperazinyl)-4-oxoquinoline-3-carboxylic acid as
colorless needles, melting point 239.0-240.5°C.
By the usual manner the hydrochloride was prepared and recrystallized from
water as colorless needles, melting point 290-300°C (decomp.).
Therapeutic Function
Antibacterial
Pharmaceutical Applications
A difluoropiperazinyl quinolone formulated as the hydrochloride salt for oral administration. The in-vitro activity is very similar to that of norfloxacin . It is active against Enterobacteriaceae and fastidious Gram-negative bacilli, including L. pneumophila. Activity against Campylobacter spp., Ps. aeruginosa, Acinetobacter and Chlamydia spp. is poor. It has reduced activity against staphylococci and poor activity against streptococci, L. monocytogenes, anaerobes and Mycobacterium spp.
A 400 mg oral dose achieves a concentration of 3–5 mg/L after 1–1.5 h. In escalating oral doses of 100, 400 and 800 mg to volunteers, the AUC was essentially proportional to the dosage, the mean plasma concentrations following 100, 400 and 800 mg doses being approximately 1.1, 4.7 and 7.5 mg/L, respectively.
Several metabolites have been described, accounting for <5% of the oral dose. Elimination occurs principally via the kidneys and 50–70% of a dose appears in the urine over 24 h. In patients with impaired renal function given 400 mg orally, the apparent elimination half-life ranged from 8 to 44 h, depending on the degree of renal failure. Non-renal clearance was also impaired, but there was no significant change in other pharmacokinetic parameters. The daily dosage (400 mg) should be reduced to 280 mg when the creatinine clearance falls below 30 mL/min. Hemodialysis has no effect on the plasma concentration. The effect of lomefloxacin on the plasma concentration of theophylline is clinically insignificant and no dosage adjustment is required.
The main adverse event is phototoxicity; other adverse events (mainly diarrhea, abdominal pain, skin reactions, dizziness, headache and insomnia) occur in about 10% of patients.
It is chiefly used in urinary tract infection, but is no longer widely available.
Clinical Use
1-Ethyl-6,8-difluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid (Maxaquin) is adifluorinated quinolone with a longer elimination half-life(7–8 hours) than other members of its class. It is the onlyquinolone for which once-daily oral dosing suffices. The oralbioavailability of lomefloxacin is estimated to be 95% to98%. Food slows, but does not prevent, its oral absorption.The extent of biotransformation of lomefloxacin is only about5%, and high concentrations of unchanged drug, rangingfrom 60% to 80%, are excreted in the urine. The comparativelylong half-life of lomefloxacin is apparently because ofits excellent tissue distribution and renal reabsorption and not because of plasma protein binding (only ～10%) or enterohepaticrecycling (biliary excretion is estimated to be ～10%).
Lomefloxacin has been approved for two primary indications. First, it is indicated for acute bacterial exacerbations of chronic bronchitis caused by H. influenzae or Moraxella (Branhamella) catarrhalis, but not if Streptococcus pneumoniae is the causative organism. Second, it is used for prophylaxis of infection following transurethral surgery. Lomefloxacin also finds application in the treatment of acute cystitis and chronic urinary tract infections caused by Gram-negative bacilli.
